logo

NKTR

Nektar Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.37 / 10
Netural

Mixed fundamental quality with several red flags: Total operating revenue YoY growth at -51.7% and Operating revenue YoY growth at -51.7% signal shrinking sales. However, Interest coverage ratio of 15.5% provides some cushion. Net income and cash metrics are also lagging, suggesting defensive positioning is prudent.

Fundamental(4.37)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-4.50
Score3/3
Weight21.16%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value-51.73
Score1/3
Weight-1.24%
1M Return-0.79%
Days sales outstanding
Value72.55
Score1/3
Weight-2.33%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight16.87%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight16.89%
1M Return8.45%
PB-ROE
Value34.08
Score3/3
Weight22.88%
1M Return12.83%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.69%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-51.73
Score1/3
Weight-1.19%
1M Return-0.76%
Asset-MV
Value-0.50
Score0/3
Weight12.05%
1M Return5.75%
Cash-MV
Value-0.07
Score2/3
Weight16.59%
1M Return8.41%
Is NKTR fundamentally strong?
  • NKTR scores 4.37/10 on fundamentals and holds a Fair valuation at present. Backed by its -175.55% ROE, -192.87% net margin, -6.20 P/E ratio, 8.80 P/B ratio, and 39.78% earnings growth, these metrics solidify its Netural investment rating.